



Laparoscopic versus open liver resection for huge hepatocellular carcinoma ($\geq$ than 10 cm): a multicenter propensity score-matched analysis from Eastern and Western referral centers

Gianluca Cassese^{1,2,3}  · Fabio Giannone^{1,4} · Federica Cipriani⁵ · Antonio Cubisino⁶ · Bruno Branciforte⁷ · Alessandro Tropea⁸ · Fabio Benedetti⁹ · Fabrizio Romano⁹ · Salvatore Gruttadauria⁸ · Guido Torzilli⁷ · Mickael Lesurtel⁶ · Luca Aldrighetti⁵ · Ho-Seong Han² · Patrick Pessaux^{4,10} · Fabrizio Panaro^{1,3}

Received: 21 November 2025 / Accepted: 11 January 2026 / Published online: 27 January 2026
© The Author(s) 2026

Abstract

Background There is still poor evidence about the safety and feasibility of minimally invasive liver surgery (MILS) for huge (> 10 cm) hepatocellular carcinomas (HCC). The aim of this study was to assess the short- and long- term outcomes of MILS versus open liver resection (OLR) for patients with huge HCC.

Methods Data regarding all consecutive patients undergoing liver resection for huge HCC were retrospectively collected from Asian (South Korean) and European (Italian and French) referral HPB centers. The cases were propensity score matched for age, center, extent of the resection, tumor size, and tumor number.

Results A total of 198 patients were included in the study. Before matching there were statistically significant differences in tumor size ($p < 0.01$) and rates of major hepatectomies performed ($p = 0.03$). After PSM two cohorts of 39 patients were obtained, with no statistically significant differences in all the compared preoperative characteristics. No significant differences were found in terms of major complications, in-hospital mortality, and operative time, between the matched cohorts. The median length of hospital stay was significantly lower after MILS (7 vs. 10 days, $p < 0.01$), as well as the median intraoperative estimated blood loss (500 ml vs 800 ml, respectively; $p = 0.02$) and the rates of intraoperative transfusions (25.6% vs 48.7%, respectively; $p = 0.03$). After a median follow-up of 52 months, there were no significant differences between OLR and MILS in median OS (44 vs. 93.6 months, respectively; $p = 0.07$). Median DFS was improved after MILS (49.8 vs. 7 months, respectively; $p < 0.01$).

Conclusion MILS for huge HCC can be safe and effective in selected cases in referral centers, being able to reduce intraoperative blood loss, and to shorten median hospital stay.

Keywords Huge hepatocellular carcinoma · Minimally invasive liver surgery · Hepatocellular carcinoma

Hepatocellular carcinoma (HCC) is the most common primary liver cancer, being listed as the seventh most common cancer worldwide and the third leading cause of cancer-related death [1]. Despite both medical and surgical improvements, HCC prognosis is still poor, with 5 years overall survival (OS) as low as 20% [2]. Surgery represents the cornerstone treatment for early-stage HCC, leading to better survival outcomes, reaching up to 50–70% of 5 years OS. Ideally, liver transplantation (LT) is the best available therapy for HCC, aiming to treat both HCC and underlying chronic liver disease, but it must face the problems of organ

shortage, with a consequent risk of dropout from waiting list and tumor progression [3]. Furthermore, the Milan criteria restrict LT in adults to patients with nodules smaller than 5 cm, or less than 3 lesions and each one not exceeding 3 cm, without vascular invasion, without extrahepatic involvement [4]. Therefore, liver resection still represents the most performed treatment for early stages.

HCC is often diagnosed in advanced stages, with large (> 5 cm) or huge lesions (> 10 cm) [5]. These patients cannot benefit from LT, neither can undergo thermal ablation due to the impossibility to achieve complete tumor necrosis of nodule larger than 3 cm [6]. Nonetheless, according to current guidelines, patients with a solitary HCC and preserved liver function can still benefit from liver resection,

when preserving enough FRL to sustain liver metabolic activity [7]. Extended resections of a cirrhotic liver may be required for such cases, with the subsequent risk of postoperative morbidity and mortality, mainly related to post-hepatectomy liver failure (PHLF) [8]. In this setting, liver resection has shown survival advantages when compared to trans-arterial chemoembolization (TACE) [9]. In patients with huge HCC, the presence of extrahepatic collaterals is a limitation for achieving the complete embolization of the tumor [10]. An alternative to surgery in such cases may be trans-arterial radioembolization (TARE). However, there is no evidence about any advantage of TARE on surgery in huge HCC, while the risk of pulmonary complications of the radioembolization in this setting is non-neglectable.

Last European guidelines about HCC treatment recommend the use of minimally invasive liver surgery (MILS) for early staged tumors, in light of a reduced risk of decompensation in case of cirrhosis, enhanced recovery, and less intraoperative blood loss, while achieving equivalent long-term oncological outcomes than open liver resection (OLR) [7, 11, 12]. Nonetheless, several difficult situations still limit the universal adoption of MILS for HCC treatment [13]. Despite few small-sized retrospective studies showed some encouraging data about the outcomes of MILS for huge HCC, this setting certainly represents a challenging and debated indication for MILS [14].

The aim of this study is to analyze postoperative outcomes of MILS for patients with huge HCC.

Methods

Patients and data

Data from consecutive patients undergoing laparoscopic liver resection for large HCC from January 2010 to September 2022 at 7 tertiary referral HPB centers across Europe and Asia were retrospectively collected from prospectively established databases. The inclusion criteria were as follows: male or female patients aged ≥ 18 years old; one or more nodules with histopathological confirmation of HCC ≥ 100 mm; no extrahepatic disease; adequate FRL. The exclusion criteria were as follows: liver resection extended to other abdominal organs other than gallbladder; histological finding of combined HCC and cholangiocarcinoma. According to the different surgical procedures, patients were divided into two groups as follows: the MILS group and the OLR group. Primary outcomes were postoperative results, while survival outcomes constituted secondary endpoints.

This study was conducted according to the Strengthening and Reporting of Observational Studies in Epidemiology (STROBE) guidelines of the EQUATOR network. Informed consent was obtained prior to every surgical procedure [15]. All subjects gave their informed consent, and the study was

conducted in accordance with the Declaration of Helsinki after institutional review board approval.

Preoperative management

The choice of the therapeutic management of each of the included patients was taken after a multidisciplinary team meeting including hepatologists, oncologists, and radiologists. Preoperative and postoperative management, as well as surgical procedures, were performed by the same team in the same facility. Preoperative evaluations were similar in both groups and included routine blood tests, liver function, coagulation examinations, alpha-fetoprotein (AFP) levels, and triphasic enhanced computed tomography (CT) and/or magnetic resonance imaging (MRI). The definition of resectable HCC was based on multidisciplinary team decision, according to comprehensive evaluation of liver function test, remnant liver volume, and liver compensation status [16].

All the included centers are referral HPB centers performing both MILS and OLR. After surgeons fully informing the patients about the pros and cons of the two approaches, the final decision was made by surgeons' and patients' preferences. The proximity of major vessels, with the subsequent risk of ischemia of the remnant liver or R1 resection, as well as the size of the lesions, were the main factors to decide the type and the extent of the resection. A major hepatectomy was carried out in cases of proximity of the first- and second-order vascular branches and/or presence of huge lesions occupying a hemiliver.

Postoperative management and follow-up

Postoperative follow-up data were analyzed. Postoperative complications were classified according to the Clavien–Dindo classification, with severe complications defined as Clavien–Dindo ≥ 3 . PHLF, post-hepatectomy bile leakage (PHBL), and post-hepatectomy hemorrhage (PHH) were diagnosed and classified according to the International Study Group of Liver Surgery (ISGLS) guidelines. Ascites was defined according to the International Ascites Club definition.

All patients were examined in outpatient clinics within 1 month after discharge, undergoing clinical, biological, and imaging evaluations every 3–4 months after discharge for the first 2 years, according to the oncological protocols. Following controls were scheduled every 6 months if no relapse was found. In case of tumor recurrence, the case was re-examined by a multidisciplinary team (MDT) with the aim of carrying out curative treatment as much as possible. The first therapeutic strategy for localized recurrent HCC was repeat hepatectomy, according to previous studies that have shown the same OS and DFS as primary liver resection. In cases where liver resection was not indicated because of liver, as well as tumor

or patient status, other locoregional therapies represented the second choice.

Statistical analysis

Continuous data are expressed as mean and standard deviation (SD) or median and inter-quartile range (IQR), depending on whether they had a normal distribution or not. Group comparisons were performed using Student's *t* test or Wilcoxon's rank test, depending on the distribution of the variable. Categorical data are expressed as frequencies and associated percentages. Comparisons between groups were performed using Pearson's chi-squared test or Fisher's exact test, depending on the expected value of the variable of interest. Overall and recurrence-free survival analyses were performed using the Kaplan–Meier method to calculate the median and 95% confidence interval (CI), and comparisons were performed using the log-rank method. The median follow-up was analyzed using the inverse Kaplan–Meier method. To compare the two cohorts by minimizing the selection bias, a propensity score-matched (PSM) analysis was performed with a caliper width of 0.50, obtaining a one-to-one match, and excluding patients in whom the PSM was not applicable. The model was based on logistic regression, using the single nearest neighbor matching method without replacement. The two groups were matched for: age, center, cirrhosis, tumor size, extent of the resection. *P* values < 0.05 were considered statistically significant. All statistical analyses were performed using SPSS software version 26 (IBM SPSS Inc. Chicago, IL).

Results

Patients and characteristics

One hundred and ninety-seven consecutive patients undergoing liver resection for huge HCC were included, of which 158 (80.2%) were laparotomic and 39 (19.8%) were minimally invasive.

Before matching, there were statistically significant differences between the 2 groups in tumor sizes (median 130 mm in OLR [60] vs. 105 mm in MILS [17]) and in the rates of major hepatectomies (74.1% in OLR [*n* = 117] vs 56.4% in MILS [*n* = 22]).

After propensity score matching, two cohorts of 39 patients were obtained. There were no statistically significant differences between the cohorts. Median age was 64 years (IQR = 25) in OLR patients vs. 63 years (IQR = 20) in MILS patients (*P* value = 0.80). Underlying liver cirrhosis was present in 17 patients undergoing OLR (43.6%) vs 15 in MILS group (38.5%) (*p* = 0.64). Median tumor size was 110 mm (IQR = 17) vs. 105 mm (IQR = 21), respectively (*P* value = 0.18), with 29

patients undergoing open major hepatectomy and 22 patients undergoing minimally invasive major liver resection (*p* = 0.10).

All preoperative patients' and tumors' characteristics are shown in Table 1.

Perioperative outcomes

The matched cohorts showed no significant differences in operative time, as well as in postoperative PHH, PHLF, severe complication rates, and in-hospital mortality. MILS cohort showed reduced median estimated blood loss (EBL) (500 ml vs. 800 ml, respectively; *P* value = 0.02), lower rates of intraoperative transfusions (25.6% vs. 48.7%, respectively; *P* value = 0.03), and shorter median length of stay (7 days vs. 10 days, respectively; *P* value < 0.01). OLR had shorter Pringle maneuver duration (0' vs. 17', respectively; *P* value = 0.04). Perioperative outcomes comparison after propensity score matching is available in Table 2.

Survival outcomes

After a median follow-up of 52 months (95% CI 40–66), there were no statistically significant differences in median OS, despite a tendency to an improved survival after MILS (44 months after OLR [95% CI 27.6–60.4] vs. 93.6 months after MILS [95% CI 34.4–153.8]; *P* value = 0.07). Median DFS was significantly better after MILS (49.8 months after MILS [95% CI 30.3–67.5] vs. 7 months after OLR [95% CI 4.3–9.7]; *P* value < 0.01). Survival outcomes are reported in Fig. 1.

Discussion

This study represents the first multicenter study investigating the short- and long-term outcomes of MILS for huge HCC, with the largest sample size in literature.

Previous studies investigating the role of laparoscopic liver resection for large liver cancer showed how it can be performed safely, concluding that tumor size does not affect both short- and long-term outcomes [18, 19]. Nonetheless, MILS for large tumors may be challenging because of limited surgical view, limited possibility of handling the underlying fibrotic or cirrhotic liver, and the proximity of such lesions to vascular and biliary structures. Indeed, tumor size is one of the main parameters of the most used difficulty scores for MILS, and an interesting recent study reports a correlation between technical difficulty and long-term results after minimally invasive liver resection [16, 20]. Therefore, MILS for huge HCC has to be considered even more technically demanding and is currently performed only by experienced surgeons in referral HPB centers.

Table 1 Preoperative patients' and tumors' characteristics before and after propensity score matching

	Before matching			After matching		
	Open (<i>n</i> = 158)	Minimally invasive (<i>n</i> = 39)	<i>P</i> value	Open (<i>n</i> = 39)	Minimally invasive (<i>n</i> = 39)	<i>P</i> value
Age, median (IQR)	64 (18.6)	63 (20.7)	0.98	64 (25)	63 (20)	0.80
Female sex, <i>n</i> (%)	45 (28.5)	6 (15.4)	0.09	3 (7.7)	6 (15.4)	0.28
BMI, median (IQR)	24.6 (4.6)	25.6 (2.7)	0.22	24.4 (4)	25.6 (2.7)	0.15
ASA score, <i>n</i> (%)						
1	26 (16.4)	2 (5.1)	0.15	0 (0)	2 (5.1)	0.21
2	74 (46.9)	24 (61.6)		21 (53.8)	24 (61.6)	
3	54 (34.2)	13 (33.3)		16 (41.1)	13 (33.3)	
4	4 (2.5)	0 (0)		2 (5.1)	0 (0)	
Cirrhosis, <i>n</i> (%)	39 (24.7)	15 (38.5)	0.08	17 (43.6)	15 (38.5)	0.64
Child, <i>n</i> (%)						
A	36 (92.3)	14 (93.4)	0.89	12 (70.6)	13 (86.6)	0.23
B	3 (7.7)	1 (6.6)		5 (19.4)	2 (13.4)	
Tumor size, median (IQR)	130 (60)	105 (21)	< 0.01	110 (17)	105 (21)	0.18
Tumor number, <i>n</i> (%)						
1	138 (87.3)	35 (89.8)	0.64	35 (89.8)	35 (89.8)	1.00
2	15 (9.5)	2 (5.1)		2 (5.1)	2 (5.1)	
≥ 3	5 (3.2)	2 (5.1)		2 (5.1)	2 (5.1)	
Major hepatectomy, <i>n</i> (%)	117 (74.1)	22 (56.4)	0.03	29 (74.3)	22 (56.4)	0.10
AFP, median (IQR)	39 (839)	20 (410)	0.46	10 (287)	20 (410)	0.77
Microvascular invasion, <i>n</i> (%)	103 (65.1)	22 (56.4)	0.23	26 (66.6)	22 (56.4)	0.35
Satellite nodules, <i>n</i> (%)	65 (41.1)	9 (23.1)	0.03	8 (20.5)	8 (20.5)	0.90
Grading, <i>n</i> (%)						
1	38 (24)	10 (25.6)	0.75	5 (12.8)	10 (25.6)	0.09
2	71 (44.9)	14 (35.8)		10 (25.6)	14 (35.8)	
3	49 (31.1)	15 (38.4)		24 (61.5)	15 (38.4)	

Bold indicates statistically significant values

IQR inter-quartile range, *BMI* body mass index, *ASA* American Society of Anesthesiologist classification, *AFP* alpha-fetoprotein

Table 2 Perioperative outcomes of matched cohorts


	Open (<i>n</i> = 39)	Minimally invasive (<i>n</i> = 39)	<i>P</i> value
Operative time, median (IQR)	300 (145)	269 (160)	0.45
Pringles maneuver duration, median (IQR)	0 (20)	17 (45)	0.04
EBL, median (IQR)	800 (800)	500 (700)	0.02
Blood transfusions, <i>n</i> (%)	19 (48.7)	10 (25.6)	0.03
PHLF, <i>n</i> (%)	3 (7.7)	2 (5.1)	0.64
PHH, <i>n</i> (%)	1 (2.6)	0 (0)	0.31
Severe complications, <i>n</i> (%)	8 (20.5)	5 (12.8)	0.36
Length of stay, median (IQR)	10 (6)	7 (7)	< 0.01
In hospital mortality, <i>n</i> (%)	1 (2.6)	1 (2.6)	1.00

Bold indicates statistically significant values

IQR inter-quartile range, *EBL* estimated blood loss, *PHLF* post-hepatectomy liver failure, *PHH* post-hepatectomy hemorrhage

In our study, after propensity score matching the data from consecutive patients with huge HCC from referral HPB center, MILS showed improved postoperative outcomes for patients with huge HCC, thanks to reduced median EBL, lower rates of intraoperative transfusions, and shorter median length of stay. This result is coherent with previous literature that has reported reduced bleeding for large HCC undergoing laparoscopic liver resection [21]. Furthermore, intraoperative bleedings have previously been related to impaired long-term oncological outcomes in HCC patients [17]. Therefore, efforts to minimize both EBL and intraoperative transfusions during hepatic resection are important for improving long-term prognosis in HCC patients. On the other hand, OLR was associated with shorter Pringle maneuver duration. However, despite longer, the median time was only 17' in MILS patients that is a relatively short duration in line with previous literature [22]. To note the indications and the threshold for Pringle maneuver application was not a priori established: every surgeon decided based on the specific case and his experience or preference.

Fig. 1 Survival outcomes after open liver resection (blue) and minimally invasive liver surgery (red)



Similarly, the reduced length of hospital stay after MILS has been often reported in various situations, including large HCC or elderly patients [23, 24]. Indeed, a previous single-center study from Seoul National University Bundang Hospital already showed a reduced stay after laparoscopic liver resection for huge HCC [25]. These results could be related to reduced postoperative pain, early ambulation, and early recovery of gastrointestinal function [26]. Moreover, a reduced length of hospital stay could lead to a significant reduction in the economic costs related to HCC treatment. However, the economic aspects were not within the aims of our study: further efforts should investigate such an important field.

When focusing on long-term outcomes, liver resection has been shown to be the best treatment for huge HCC, when compared to other strategies [27]. Long-term recurrence is the main problem to face in these patients, and several prognostic risk factors have been identified, such as T4 status, macrovascular portal invasion, and the use of intraoperative transfusion by Yamashita and al., or serum alpha-fetoprotein ≥ 100 ng/mL, hypermetabolic uptake on positron emission tomography, satellite nodules, and microvascular invasion [28]. In case of recurrence, timely and aggressive treatment is able to significantly improve long-term survival of HCC patients, with recurrent surgery always to be chosen in the optic of a hierarchic

strategy and a personalized management of HCC patients [29]. Within the entire cohort of the patients included in our study the median OS was 56 months [95% CI 41.6–70.3]. Such encouraging results are in line with previous literature and confirm the leading role of surgery for huge HCC patients. Interestingly, both median OS and DFS were improved in the MILS group. However, such results must be interpreted with caution, since many prognostic factors, such as some pathological characteristics of the tumors were not analyzed, because of some missing data. Further appropriate studies should investigate this aspect.

This study has some other limitations. Firstly, its retrospective nature may lead to selection bias. Nonetheless, a propensity score matching was applied to reduce them as much as possible. Furthermore, all consecutive patients meeting the selection criteria were included. Secondly, the multicenter nature may add some heterogeneity to analysis and results, since treatments and managements may somehow vary among centers. As previously stated, the survival outcomes were not analyzed through a multivariable analysis due to the lack of some important additional data.

Finally, this study may play a role in confirming the role of MILS for the surgical treatment of huge HCC. Indeed, the lack of large sample sized studies, as well as propensity score-matched analysis, has lead many centers to consider huge HCC not indicated for MILS. If further studies will confirm our results, huge HCC may be considered safe and feasible for a minimally invasive approach in referral centers, and it may be included in current recommendations.

Conclusion

MILS is a safe option for huge HCC, in selected cases and in referral centers. In this setting, it may reduce intraoperative bleeding and postoperative length of hospital stay, while ensuring good long-term oncological outcomes.

Author contributions Gianluca Cassese wrote the manuscript; Fabio Giannone was responsible for planning the study and handling the data; Federica Cipriani, Antonio Cubisino, Bruno Branciforte, Alessandro Tropea, and Fabio Benedetti were responsible for data collection; Fabrizio Romano, Salvatore Gruttadauria, Guido Torzilli, Mickael Lesurtel, Luca Aldrighetti, Ho-Seong Han, and Patrick Pessaux critically revised the manuscript.

Funding Open access funding provided by Università degli Studi del Piemonte Orientale Amedeo Avogadro within the CRUI-CARE Agreement.

Declarations

Disclosures Fabio Giannone, Gianluca Cassese, Federica Cipriani, Antonio Cubisino, Bruno Branciforte, Alessandro Tropea, Fabio Benedetti, Fabrizio Romano, Salvatore Gruttadauria, Guido Torzilli, Mickael Lesurtel, Luca Aldrighetti, Ho-Seong Han, Patrick Pessaux, and Fabrizio Panaro have no conflicts of interest or financial ties to disclose.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

References

1. Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A (2025) Cancer statistics, 2025. *CA Cancer J Clin* 75(1):10–45
2. Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S et al (2021) Hepatocellular carcinoma. *Nat Rev Dis Primers* 7(1):6
3. Magyar CTJ, Rajendran L, Li Z, Banz V, Vogel A, O’Kane GM et al (2025) Precision surgery for hepatocellular carcinoma. *Lancet Gastroenterol Hepatol* 10(4):350–368
4. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F et al (1996) Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. *N Engl J Med* 334(11):693–699
5. Ducreux M, Abou-Alfa GK, Bekaii-Saab T, Berlin J, Cervantes A, de Baere T, et al (2023) The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022. *ESMO Open* 8(3):101567
6. Crocetti L, de Baere T, Pereira PL, Tarantino FP (2020) CIRSE standards of practice on thermal ablation of liver tumours. *Cardiovasc Intervent Radiol* 43(7):951–962
7. European Association for the Study of the L (2025) EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma. *J Hepatol* 82(2):315–374
8. Cassese G, Han HS, Al Farai A, Guiu B, Troisi RI, Panaro F (2022) Future remnant liver optimization: preoperative assessment, volume augmentation procedures and management of PVE failure. *Minerva Surg* 77(4):368–379
9. Bogdanovic A, Bulajic P, Masulovic D, Bidzic N, Zivanovic M, Galun D (2021) Liver resection versus transarterial chemoembolization for huge hepatocellular carcinoma: a propensity score matched analysis. *Sci Rep* 11(1):4493
10. Chung JW, Kim HC, Yoon JH, Lee HS, Jae HJ, Lee W et al (2006) Transcatheter arterial chemoembolization of hepatocellular carcinoma: prevalence and causative factors of extrahepatic collateral arteries in 479 patients. *Korean J Radiol* 7(4):257–266
11. Wang YQ, Tan ZK, Peng Z, Huang H (2025) A systematic review and meta-analysis of the comparison of laparoscopic radiofrequency ablation to percutaneous radiofrequency ablation for hepatocellular carcinoma. *Front Oncol* 15:1559343
12. Kabir T, Tan ZZ, Syn NL, Wu E, Lin JD, Zhao JJ et al (2021) Laparoscopic versus open resection of hepatocellular carcinoma in patients with cirrhosis: meta-analysis. *Br J Surg* 109(1):21–29
13. Cassese G, Han HS, Lee B, Lee HW, Cho JY, Troisi R (2022) Leap-ing the boundaries in laparoscopic liver surgery for hepatocellular carcinoma. *Cancers (Basel)*. <https://doi.org/10.3390/cancers14082012>
14. Kabir T, Syn NL, Guo Y, Lim KI, Goh BKP (2021) Laparoscopic liver resection for huge (≥ 10 cm) hepatocellular carcinoma: a coarsened exact-matched single-surgeon study. *Surg Oncol* 37:101569

15. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP et al (2007) The Strengthening of Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *Lancet* 370(9596):1453–1457
16. Lv X, Zhang L, Yu X, Yu H (2023) The difficulty grade of laparoscopic hepatectomy for hepatocellular carcinoma correlates with long-term outcomes. *Updates Surg* 75(4):881–888
17. Suh SW, Lee SE, Choi YS (2023) Influence of intraoperative blood loss on tumor recurrence after surgical resection in hepatocellular carcinoma. *J Pers Med* 13(7)
18. Ding DY, Liu L, Lin KY, Gan XJ, Guo XG, Ding WB et al (2023) Perioperative and long-term survival outcomes of laparoscopic versus open hepatectomy for BCLC stage A large hepatocellular carcinoma patients in difficult segments: a two-centre, propensity score matching analysis. *Front Oncol* 13:1095357
19. Goh BK, Chow PK, Teo JY, Wong JS, Chan CY, Cheow PC et al (2014) Number of nodules, Child-Pugh status, margin positivity, and microvascular invasion, but not tumor size, are prognostic factors of survival after liver resection for multifocal hepatocellular carcinoma. *J Gastrointest Surg* 18(8):1477–1485
20. Ban D, Tanabe M, Ito H, Otsuka Y, Nitta H, Abe Y et al (2014) A novel difficulty scoring system for laparoscopic liver resection. *J Hepatobiliary Pancreat Sci* 21(10):745–753
21. Chiang MH, Tsai KY, Chen HA, Wang WY, Huang MT (2021) Comparison of surgical outcomes for laparoscopic liver resection of large hepatocellular carcinomas: a retrospective observation from single-center experience. *Asian J Surg* 44(11):1376–1382
22. Ortiz Galindo SA, Haber PK, Benzing C, Krenzien F, Riddermann A, Frisch O et al (2022) Safety of intermittent Pringle maneuver during minimally invasive liver resection in patients with hepatocellular carcinoma with and without cirrhosis. *Langenbecks Arch Surg* 407(1):235–244
23. Cassese G, Giannone F, Cipriani F, Cubisino A, Rhaïem R, Branciforte B et al (2025) Laparoscopic versus open liver resection for large (≥ 5 cm) hepatocellular carcinoma in elderly patients: a multicenter propensity score-matched study. *Updates Surg* 77(3):665–674
24. Peng Z, Zhu ZR, He CY, Huang H (2025) A meta-analysis: laparoscopic versus open liver resection for large hepatocellular carcinoma. *Minim Invasive Ther Allied Technol* 34(1):24–34
25. Cassese G, Han HS, Lee B, Lee HW, Cho JY (2024) Laparoscopic versus open liver resection for huge hepatocellular carcinoma (≥ 10 cm): a retrospective analysis from a high-volume referral center. *Surg Endosc* 38(11):6324–6331
26. Cho JY, Han HS, Yoon YS, Lee HW, Lee B, Park Y et al (2025) Current status and future perspectives of minimally invasive liver surgery for hepatocellular carcinoma. *J Liver Cancer*. <https://doi.org/10.17998/jlc.2025.08.18>
27. Cai X, Wu S (2022) Transarterial chemoembolization versus surgical resection for giant hepatocellular carcinoma under the different status of capsule: a retrospective study. *Transl Cancer Res* 11(12):4359–4372
28. Hwang S, Lee YJ, Kim KH, Ahn CS, Moon DB, Ha TY et al (2015) Long-term outcome after resection of huge hepatocellular carcinoma ≥ 10 cm: single-institution experience with 471 patients. *World J Surg* 39(10):2519–2528
29. Herrero A, Toubert C, Bedoya JU, Assenat E, Guiu B, Panaro F et al (2024) Management of hepatocellular carcinoma recurrence after liver surgery and thermal ablations: state of the art and future perspectives. *Hepatobiliary Surg Nutr* 13(1):71–88

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Authors and Affiliations

Gianluca Cassese^{1,2,3}  · Fabio Giannone^{1,4} · Federica Cipriani⁵ · Antonio Cubisino⁶ · Bruno Branciforte⁷ · Alessandro Tropea⁸ · Fabio Benedetti⁹ · Fabrizio Romano⁹ · Salvatore Gruttadauria⁸ · Guido Torzilli⁷ · Mickael Lesurtel⁶ · Luca Aldrighetti⁵ · Ho-Seong Han² · Patrick Pessaux^{4,10} · Fabrizio Panaro^{1,3}

✉ Fabio Giannone
Fabio.giannone@ospedale.al.it

¹ Division of Hepato-Pancreato-Biliary, Oncologic and Robotic Surgery, Department of Research and Innovation (DAIRI), Azienda Ospedaliero-Universitaria SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy

² Division of Hepato-Pancreato-Biliary Surgery, Department of Surgery, Seoul National University Bundang Hospital, Seongnam, South Korea

³ Department of Health Sciences, University of Eastern Piedmont “Amedeo Avogadro”, Azienda Ospedaliero-Universitaria SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy

⁴ Department of Visceral and Digestive Surgery, University Hospital of Strasbourg, Strasbourg, France

⁵ Hepatobiliary Surgery Division, IRCCS San Raffaele Scientific Institute, Milan, Italy

⁶ Department of HPB Surgery and Liver Transplantation, Beaujon Hospital, APHP, University of Paris Cité, Clichy, France

⁷ Division of Hepatobiliary and General Surgery, Department of Surgery, Humanitas Clinical and Research Center - IRCCS, Humanitas University, Rozzano, Milan, Italy

⁸ Department for the Treatment and Study of Abdominal Diseases and Abdominal Transplantation, IRCCS-ISMETT, UPMC (University of Pittsburgh Medical Center), Palermo, Italy

⁹ Department of General Surgery, Unit of Hepatobiliary Surgery, IRCCS San Gerardo dei Tintori, Milano-Bicocca University, Monza, Italy

¹⁰ Inserm, U1110, Institut de Recherche sur les Maladies Virales et Hépatiques, Université de Strasbourg, Strasbourg, France